Oral Abstract Session: Urothelial Carcinoma; and Adrenal, Penile, Testicular, and Urethral Cancers
The authors conclude: This trial establishes RPLND as a therapeutic option as a first-line treatment in early metastatic seminoma. The surgery offers cancer control rates similar to those seen in non-seminomatous germ cell tumors. Clinical trial information: NCT02537548
Rapid Abstract Session: Urothelial Carcinoma and Rare Tumors
et al.
The authors conclude: With a CR rate of 72%, N-803 has met its primary endpoint with 59% probability of CR patients maintaining CR for at least 12 months. With the observed strong efficacy and an SAE rate of 1%, N-803 represents a novel treatment option for BCG unresponsive CIS with a favorable benefit:risk ratio, in a therapeutically challenging disease. Clinical trial information: NCT03022825